Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Detection of intracranial metastases - A multicenter, intrapatient comparison of gadobenate dimeglumine - Enhanced MRI with routinely used contrast agents at equal dosage
Autore:
Colosimo, C; Ruscalleda, J; Korves, M; La Ferla, R; Wool, C; Pianezzola, P; Kirchin, MA;
Indirizzi:
Bracco SpA, Med Affairs Europe, I-20134 Milan, Italy Bracco SpA Milan Italy I-20134 Med Affairs Europe, I-20134 Milan, Italy Univ G Annunzio, Inst Radiol Sci, Chieti, Italy Univ G Annunzio Chieti Italy G Annunzio, Inst Radiol Sci, Chieti, Italy Hosp Santa Cruz & San Pablo, E-08025 Barcelona, Spain Hosp Santa Cruz & San Pablo Barcelona Spain E-08025 025 Barcelona, Spain Free Univ Berlin, Charite, Radiol Klin, D-1000 Berlin, Germany Free Univ Berlin Berlin Germany D-1000 diol Klin, D-1000 Berlin, Germany
Titolo Testata:
INVESTIGATIVE RADIOLOGY
fascicolo: 2, volume: 36, anno: 2001,
pagine: 72 - 81
SICI:
0020-9996(200102)36:2<72:DOIM-A>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
MAGNETIZATION-TRANSFER; BRAIN METASTASES; LESIONS;
Keywords:
MRI; brain metastases; intracranial metastases; MR contrast agent; gadobenate dimeglumine; MultiHance;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: La Ferla, R Bracco SpA, Med Affairs Europe, Via Folli 50, I-20134 Milan, Italy Bracco SpA Via Folli 50 Milan Italy I-20134 0134 Milan, Italy
Citazione:
C. Colosimo et al., "Detection of intracranial metastases - A multicenter, intrapatient comparison of gadobenate dimeglumine - Enhanced MRI with routinely used contrast agents at equal dosage", INV RADIOL, 36(2), 2001, pp. 72-81

Abstract

RATIONALE AND OBJECTIVES. To compare gadobenate dimeglumine (MultiHance) with other commercially available MRI contrast agents for the detection of intracranial metastases. METHODS. A retrospective assessment was performed on MR images from 22 patients enrolled in a prior phase II clinical trial of gadobenate dimeglumine. Each patient underwent two examinations: a first examination with one of three "comparator" agents (gadopentetate dimeglumine, gadodiamide, and gadoterate meglumine) at a dosage of either 0.1 or 0.2 mmol/kg, and then a similar examination with gadobenate dimeglumine at equal dosage, All images were evaluated randomly for lesion number and location in unpaired and then paired fashion by two independent, masked neuroradiologists. A third assessorperformed quantitative assessments on the available complete sets of digitally recorded images (10 cases). RESULTS. The findings for the comparator agents were pooled. Sensitivity for lesion detection with gadobenate dimeglumine (93%-100%) was markedly superior to that of comparator-enhanced examinations (65%-73%). The increase of lesion-to-brain contrast of the main lesion was consistently greater withgadobenate dimeglumine than with comparator agents relative to unenhanced contrast (+43% vs. +27%). CONCLUSIONS. Gadobenate dimeglumine proved to be a more efficacious agent than comparator contrast agents for the detection of intracranial metastatic lesions: superior efficacy was noted by both reviewers for total lesion count as well as for sensitivity and positive predictive value for lesion detection. The higher relaxivity of gadobenate dimeglumine might explain the superior sensitivity of gadobenate dimeglumine-enhanced MRI for the detection of central nervous system metastases.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 10:15:31